Dyadic International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today the introduction of its most advanced biofuels enzyme, AlternaFuel\u00ae CMAX\u2122, at the World Biofuels Markets exhibition in Rotterdam, The Netherlands.<\/b><\/p>\n
Dyadic has recently completed its scale-up of AlternaFuel\u00ae CMAX\u2122 which was derived from Dyadic\u2019s proprietary and patented C1 platform technology. AlternaFuel\u00ae CMAX\u2122 has proven to be effective in converting multiple forms of biomass into fermentable sugars which is the critical step in the production of cellulosic ethanol and other advanced biofuels and biochemicals from non-food feedstocks.<\/p>\n
The World Biofuels Markets is Europe\u2019s largest biofuels congress and exhibition, supporting the world\u2019s development and search for alternative energy sources. All attendees of the World Biofuels Markets are welcome to visit Dyadic\u2019s stand located at Booth #9where Dyadic\u2019s leading scientists will be available to discuss specific applications of AlternaFuel\u00ae CMAX\u2122.<\/p>\n
Dyadic\u2019s President and CEO, Mark Emalfarb, will also be presenting the most recent data regarding the performance of AlternaFuel\u00ae CMAX\u2122 at the World Biofuels Markets on Wednesday, March 23rd at the Biobased Chemicals session and on Thursday, March 24th at the Advanced Biofuels session.<\/p>\n
Mr. Emalfarb stated, “Dyadic has always maintained that the best economic model for the efficient production of cellulosic sugars involves controlling the enzyme technology necessary for the on-site production of biofuels and biochemicals. The decision to make AlternaFuel\u00ae CMAX\u2122 commercially available supports this goal by providing prospective partners with greater access to these unique enzymes in a ready-to-use formulation so that they can observe their performance and flexibility in demonstrations at their own facilities. We believe that this will not only provide additional revenue to Dyadic through product sales but will also provide greater opportunity for these customers to transition from purchasing these enzymes to ultimately manufacturing them on-site under license from Dyadic.\u201d<\/p>\n
About Dyadic<\/i><\/b>
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.<\/p>\n